華東醫藥(000963.SZ):Sinclair今年亦有望實現較好增長
格隆匯2月20日丨華東醫藥(000963.SZ)於2023年2月15日14:30-16:00;2月16日11:00-11:40、14:00-15:00接受機構現場調研時表示,Sinclair目前醫美收入主要來源於Ellansé®、MaiLi系列新型高端玻尿酸、Lanluma®膠原蛋白刺激劑等核心注射類產品,旗下HighTech公司的Cooltech Define、Viora公司V系列等能量源設備產品也處在快速增長期。Sinclair去年克服了海外通脹引起的運營成本、人工成本上漲的影響,整體經營持續向好,盈利狀況也逐步改善,今年亦有望實現較好增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.